Kazuhiko Shibata

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009 · 4.1K citations

Open Label, Medicine, Cancer Growth +10

Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03

Satoshi Teramukai, Toshiyuki Kitano, Yusuke Kishida et al. · European Journal of Cancer · 2009 · 339 citations

Advanced Lung Disease, Medicine, Immunology +7

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii et al. · British Journal of Cancer · 2008 · 203 citations · Full text

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · Journal of Clinical Oncology · 2012 · 145 citations

Platinum Doublet, Surgical Oncology, Cancer Management +21

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Hiroshige Yoshioka, Mototsugu Shimokawa, Takashi Seto et al. · Annals of Oncology · 2019 · 89 citations